ADVERTISEMENT

Impact of the MTHFR C677T genetic variant on depression

Current Psychiatry. 2020 October;19(10):41-45,51,53 | doi:10.12788/cp.0052
October 1, 2020|Current Psychiatry
Madeline Lipp, PharmD;Amy Pasternak, PharmD;Kristen Ward, PharmD
Author and Disclosure Information

Dr. Lipp is a Graduate Student in Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania. Dr. Pasternak is a Clinical Pharmacist, Department of Pharmacy Services, Michigan Medicine, and Clinical Assistant Professor, Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan. Dr. Ward is a Clinical Pharmacist, Department of Pharmacy Services, Michigan Medicine, and Clinical Assistant Professor, Department of Clinical Pharmacy, University of Michigan, Ann Arbor, Michigan.

Disclosures
The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

Related Resources 

  • Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165(1):1-13.
  • Trimmer E. Methylenetetrahydrofolate reductase: biochemical characterization and medical significance. Current Pharmaceutical Design. 2013;19(4):2574-3595.

Drug Brand Names

Citalopram • Celexa
Duloxetine • Cymbalta
Escitalopram • Lexapro
Fluoxetine • Prozac
L-methylfolate • Deplin
Mirtazapine • Remeron
Paroxetine • Paxil
Sertraline • Zoloft

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT